Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-dose, Randomised, Double-blind, Two-stage, Two-way Crossover Pharmacokinetic and Pharmacodynamic Evaluation of a Biosimilar Pegfilgrastim (B12019) Versus the Reference Product Neulasta in Healthy Subjects

Trial Profile

Single-dose, Randomised, Double-blind, Two-stage, Two-way Crossover Pharmacokinetic and Pharmacodynamic Evaluation of a Biosimilar Pegfilgrastim (B12019) Versus the Reference Product Neulasta in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Neutropenia
  • Focus Pharmacodynamics; Pharmacokinetics; Registrational
  • Sponsors Cinfa Biotech

Most Recent Events

  • 23 Nov 2018 According to a Mundipharma GmbH media release, the EC has granted approval for the use of Pelmeg (pegfilgrastim) as a treatment for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy.The ECs decision follows a recommendation from the CHMP that was based on a robust regulatory submission of key biosimilarity data from analytical, biofunctional and clinical study comparisons for Pelmeg.
  • 04 Oct 2017 According to a Cinfa Biotech media release, based on the data from this and other study (see profile 276855), the European Medicines Agency (EMA) has accepted Marketing Authorisation Application (MAA) for B12019 to treat chemotherapy-induced neutropenia.
  • 12 Sep 2017 Results of this and other study (NCT02912377), presented at the 42nd European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top